Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGMS2 | Q8NHU3 | 8/20 | 0.56 |
| ▸ | SGMS1 | Q86VZ5 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GCK | P35557 | 5/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PPIA | P62937 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2337781 | 0.76 | GCK (0.71) | GCKGRM5 | |
| SCHEMBL28597283 | 0.73 | SGMS2 (0.43) | SGMS2SGMS1SMN1; SMN2GCKPKM | |
| SCHEMBL28597282 | 0.73 | SGMS2 (0.43) | SGMS2SGMS1SMN1; SMN2GCKPKM | |
| SCHEMBL29785266 | 0.72 | SGMS2 (1.00) | SGMS2SGMS1 | |
| SCHEMBL21266915 | 0.72 | SGMS2 (1.00) | SGMS2SGMS1 | |
| SCHEMBL9126609 | 0.72 | PPIA (0.53) | SGMS2SGMS1PPIA | |
| SCHEMBL9126866 | 0.72 | PPIA (0.52) | SGMS2SGMS1SMN1; SMN2PPIA | |
| SCHEMBL9127894 | 0.71 | PPIA (0.55) | SGMS2SGMS1SMN1; SMN2PPIA | |
| SCHEMBL9124740 | 0.71 | PPIA (0.55) | SGMS2SGMS1SMN1; SMN2PPIA | |
| SCHEMBL488951 | 0.70 | NPC1 (0.61) | SGMS2SGMS1SMN1; SMN2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106197-B2 | Aminoheteroaryl compounds as protein kinase inhibitors | PFIZER INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-7230098-B2 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | SUGEN, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20070072874-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | SUGEN, INC. | 2007-03-29 | — | — | US | disclosed |
| US-20050009840-A1 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | SUGEN, INC. | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009840-A1 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | MET, ERBB2, CDK4 | SGMS2 4017/4885SGMS1 3965/4885SMN1; SMN2 3718/4885 |
| US-20070072874-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | MET, MAP4K1, MAP4K2 | SGMS2 4243/4885SGMS1 3876/4885SMN1; SMN2 4186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.